In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system

Current Eye Research

Volumn 27, Issue 4, 2003, Pages 253-259

  Blondin, Catherine ^a   Hamard, Pascale ^a,b   Cholley, Béatrice ^c   Haeffner Cavaillon, Nicole ^c   Baudouin, Christophe ^a,d  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL BROUSSAIS   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Antiglaucoma medications; Benzalkonium; Complement system; Glaucoma; Inflammation

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM; BETAXOLOL; CARTEOLOL; IMMUNOGLOBULIN G; LATANOPROST; TIMOLOL; ZYMOSAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT HEMOLYSIS TEST; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; EYE INFLAMMATION; GLAUCOMA; HUMAN; IMMUNOGLOBULIN AGGREGATE; IN VITRO STUDY; INFLAMMATION; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; BENZALKONIUM COMPOUNDS; BETAXOLOL; CARTEOLOL; COMPLEMENT SYSTEM PROTEINS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 0142138814     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.27.4.253.16603     Document Type: Article

References (43)

1. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and non-glaucomatous normals. Ophthalmology. 1984;91:564-579.
2. Grierson I. What is open angle glaucoma? Eye. 1987;1:15-28.
3. Rohen JW et al. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma. Exp Eye Res. 1993;56:683-692.
4. Hamard P et al. Confocal microscopic examination of trabecular meshwork removed during ab externo trabeculectomy. Br J Ophthalmol. 2002;86:1046-1052.
5. Williams DE et al. Effects of timolol, betaxolol, and levobunolol on human Tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992;33:2233-2241.
6. Broadway DC et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
7. Yalvac IS et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
8. Baudouin C et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology. 1999;106:556-563.
9. Sherwood MB et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989;96:327-335.
10. Nuzzi R et al. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: An immunohistochemical and ultrastructural study. Graefes Arch clin Exp Ophthalmol. 1995;233:154-162.
11. Broadway DC et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454.
12. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica. 2002;216:175-179.
13. Guglielminetti E et al. HLA-DR expression in conjunctival cells after latanoprost. J Ocul Pharmacol Ther. 2002; 18:1-19.
14. Bensoussan L, Baudouin C, Blondin C, Sabeh-Afaki G, Creuzot-Garcher C et Brignole F. Analyse par cytométrie en flux de l'expression des interleukines 6 et 8 par les cellules epitheliales conjonctivales de patients glaucomateux traités au long cours. [Interleukin (IL)-6 and IL-8 expression by conjunctival epithelial cells from long-term treated glaucoma patients]. J Fr Ophthalmol. 2003;[in press].
15. Lavin MJ et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108: 1543-1548.
16. Baudouin C. Mechanisms of failure in glaucoma filtering surgery: A consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res. 1996;16:29-41.
17. Yamamoto GK, Allansmith MR. Complement in tears from normal humans. Am J Ophthalmol. 1979;88:758-783.
18. Mondino BJ, Brady KJ. Distribution of hemolytic complement in the normal cornea. Arch Ophthalmol. 1981;99:1430-1433.
19. Brawman-Mintzer O, Mondino BJ, Mayer FJ. The complement system in sclera. Invest Ophthalmol Vis Sci. 1988;29:1756-1758.
20. Mondino BJ, Sidikaro Y, Sumner H. Anaphylatoxin levels in human vitreous humor. Invest Ophthalmol Vis Sci. 1988;29:1195-1198.
21. Mondino BJ, Rao H. Hemolytic complement activity in aqueous humor. Invest Ophthalmol Vis Sci. 1983;101: 465-468.
22. Bardenstein DS et al. Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis. Immunology. 2001;104:423-430.
23. Cocuzzi E et al. Release of complement regulatory proteins from ocular surface cells in infection. Curr Eye Res. 2000;21:856-866.
24. Mondino BJ, Glovsky MM, Ghekiere L. Activated complement in inflamed aqueous humor. Invest Ophthalmol Vis Sci. 1984;25:871-873.
25. Cruz JC et al. Complement activation via the alternative pathway causes a rapid-onset anterior uveitis. Poster presentation at the ARVO meeting, 2002 May 5-10; F. Lauderdale, Florida. Available from: URL: http://www.arvo.org/ Abstracts/search02.html.
26. Gerl VB et al. Extensive deposits of complement C3d and C5b-9 in the choriocapillaries of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43:1104-1108.
27. Grisanti S et al. The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1991;32:2711-2717.
28. Baudouin C et al. Immunohistological study of subretinal membranes in age-related macular degeneration. Jpn J Ophthalmol. 1992;36:443-451.
29. Johnson LV et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
30. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
31. De Saint Jean M, Brignole F, Bringuier A-F, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619-629.
32. Harbeck RJ, Giclas PC. Complement assays. In: Diagnostic Immunology Laboratory Manual. New York: Raven Press; 1991;348-358.
33. Melena J, Wood JP, Osborne NN. Betaxolol, a beta1-antagonist, has an affinity for L-type Ca2+ channels. Eur J Pharmacol. 1999;378:317-322.
34. Imanishi J et al. Complement levels in human tears. Jpn J Ophthalmol. 1982;26:229-233.
35. Mondino BJ, Zaidman GW. Hemolytic complement in tears. Ophthalmic Res. 1983;15:208-211.
36. Mondino BJ, Rao H. Complement levels in normal and inflamed aqueous humor. Invest Ophthalmol Vis Sci. 1983;24:380-384.
37. Mondino BJ, Sumner H. Anaphylatoxin levels in human aqueous humor. Invest Ophthalmol Vis Sci. 1986;27: 1288-1292.
38. Mondino BJ, Sumner H. Complement inhibitors in normal cornea and aqueous humor. Invest Ophthalmol Vis Sci. 1984;25:483-486.
39. Morgan BP. The complement system: An overview. Methods Mol Biol. 2000;150:1-13.
40. Willcox MD et al. Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci. 1997;38:1-8.
41. Sohn JH et al. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000;41: 3492-3502.
42. Goslings WR et al. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998;39:989-995.
43. Yanagisawa S et al. effect of topical betaxolol on the acute rise of aqueous flare induced by highly selective agonists for prostaglandin E2 receptor subtypes in pigmented rabbits. Ophtalmic Res. 2002;34:48-50.